Investigational drug · Phase 2
NHS7108
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NHS7108"
First trial start
2026
Oct 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NHS7108", any sponsor or status.
Conditions studied
As listed on its trial records.
- Exocrine Pancreatic Insufficiency (EPI)
- Cystic Fibrosis (CF)
- Pancreatic Enzyme Abnormality
- Pancreatic Diseases
Approved drugs for the same conditions: Pancreatic cancer · Cystic fibrosis · Respiratory · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NHS7108" as an intervention, largest first.
Aimmune Nestlé Health Science US R&D, LLCIndustry
NCT07559175 · 66 participants (planned) · Start Oct 2026 · Primary completion Jun 2027
Drug: NHS7108; Zenpep® · For: Exocrine Pancreatic Insufficiency (EPI); Cystic Fibrosis (CF); Pancreatic Enzyme Abnormality and 1 more
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Los Angeles, California · 39 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Exocrine Pancreatic Insufficiency (EPI)
- ANG003Phase 21 trial
Anagram Therapeutics, Inc. · Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.